Overview of ibrutinib/ibrutinib production in China

Ibrutinib/Ibrutinib, as a revolutionary targeted therapy drug, has attracted widespread attention and been used in China. The original manufacturer of this drug is Pharmacyclics LLC in the United States, but in China, its production and sales are achieved through specific authorization and cooperation mechanisms.

Currently, several pharmaceutical companies in China have already produced or are preparing to produce domestic generic versions of ibrutinib. Among them, Simcere Pharmaceutical Co., Ltd. is already at the forefront. Their ibrutinib is undergoing strict review by the National Medical Products Administration. Once approved, this will mean that Chinese patients will have more treatment options and possibilities while ensuring that the ingredients of the drug are consistent with the original drug.

Ibrutinib/Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor that has shown significant efficacy in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD). Clinical in vitro studies further revealed its mechanism of action, including inducing CLL cell apoptosis, inhibiting cell survival and proliferation, hindering cell migration, and reducing the secretion of chemokines such as CCL3 and CCL4. These effects have been shown to have significant therapeutic effects in animal models.

As for the price of the drug, the original drug of ibrutinib has been launched in China in capsule form and is included in the reimbursement scope of Class B medical insurance, but only for patients who meet the indications. At present, the common specification on the market is 140mg*90 capsules, and the price of each box is about RMB 10,000. As for the price of domestic generic drugs, it has not yet been clarified, but it is expected that they will provide patients with more economic choices after they are launched.